Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy.
Blood. 2010 Feb 25;115(8):1605-9. doi: 10.1182/blood-2009-05-223586. Epub 2009 Dec 16.
Easily reproducible animal models that allow for study of the biology of chronic lymphocytic leukemia (CLL) and to test new therapeutic agents have been very difficult to establish. We have developed a novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 into Rag2(-/-)gamma(c)(-/-) mice. These mice lack B, T, and natural killer (NK) cells, and, in contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, which were successfully transplanted through either subcutaneous or intravenous routes. The result is a novel in vivo model that has systemic involvement, develops very rapidly, allows the measurement of tumor burden, and has 100% engraftment efficiency. This model closely resembles aggressive human CLL and could be very useful for evaluating both the biologic basis of CLL growth and dissemination as well as the efficacy of new therapeutic agents.
建立可重复性强的动物模型,以研究慢性淋巴细胞白血病(CLL)的生物学特性并测试新的治疗药物一直非常困难。我们通过将 CLL 细胞系 MEC1 移植到 Rag2(-/-)gamma(c)(-/-)小鼠中,建立了一种新型可移植的 CLL 异种移植鼠模型。这些小鼠缺乏 B、T 和自然杀伤 (NK) 细胞,与保留 NK 细胞的裸鼠不同,它们似乎是 MEC1 细胞的最佳受体,这些细胞可以通过皮下或静脉途径成功移植。其结果是建立了一种新型的体内模型,具有全身性的特征,发展非常迅速,可测量肿瘤负担,并且具有 100%的移植效率。这种模型非常类似于侵袭性人类 CLL,可非常有助于评估 CLL 生长和扩散的生物学基础以及新治疗药物的疗效。